A New Genetic Guide for Safer Thiopurine Dosing
The Clinical Pharmacogenetics Implementation Consortium has released an updated guideline for prescribing thiopurine drugs like azathioprine. The recommendations are based on genetic testing for two key enzymes, TPMT and NUDT15, which break down these medications. Individuals with certain genetic variants that reduce or eliminate enzyme activity are at high risk for severe side effects, including life-threatening myelosuppression, if given standard doses. The guideline provides specific, genotype-based starting dose adjustments to improve safety across diverse populations.
Why it might matter to you:
While not directly for diabetes, thiopurines like azathioprine are used off-label or in complex cases for managing autoimmune complications that can co-occur with the disease. This precision-dosing framework offers a concrete tool to mitigate a significant drug toxicity risk, which is a core concern in managing patients with chronic conditions and polypharmacy. For a clinician focused on advancing standards of care, integrating such pharmacogenetic evidence could refine therapeutic decision-making and enhance patient safety protocols.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
